- Home
- NATH vs AURA Comparison
NATH vs AURA Comparison
Compare NATH & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATH
- AURA
- Stock Information
- Founded
- NATH 1916
- AURA 2007
- Country
- NATH United States
- AURA United States
- Employees
- NATH N/A
- AURA N/A
- Industry
- NATH Restaurants
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- NATH Consumer Discretionary
- AURA Health Care
- Exchange
- NATH Nasdaq
- AURA Nasdaq
- Market Cap
- NATH 385.4M
- AURA 370.1M
- IPO Year
- NATH N/A
- AURA 2021
- Fundamental
- Price
- NATH $94.61
- AURA $5.81
- Analyst Decision
- NATH
- AURA Strong Buy
- Analyst Count
- NATH 0
- AURA 4
- Target Price
- NATH N/A
- AURA $22.75
- AVG Volume (30 Days)
- NATH 10.7K
- AURA 383.7K
- Earning Date
- NATH 02-06-2025
- AURA 03-24-2025
- Dividend Yield
- NATH 2.11%
- AURA N/A
- EPS Growth
- NATH 24.88
- AURA N/A
- EPS
- NATH 5.80
- AURA N/A
- Revenue
- NATH $146,386,000.00
- AURA N/A
- Revenue This Year
- NATH N/A
- AURA N/A
- Revenue Next Year
- NATH N/A
- AURA N/A
- P/E Ratio
- NATH $16.34
- AURA N/A
- Revenue Growth
- NATH 6.83
- AURA N/A
- 52 Week Low
- NATH $64.02
- AURA $5.77
- 52 Week High
- NATH $104.96
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- NATH 52.94
- AURA 31.72
- Support Level
- NATH $92.64
- AURA $5.77
- Resistance Level
- NATH $97.00
- AURA $6.36
- Average True Range (ATR)
- NATH 1.80
- AURA 0.45
- MACD
- NATH -0.27
- AURA -0.13
- Stochastic Oscillator
- NATH 67.68
- AURA 14.29
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.